Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.

Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87% in second quarter, generally outpacing its peers, as it aims to more than double its fulfillment capacity this year Company’s shares now trade around $6.50, well off a $23 high reached in February, as investors worry about regulatory wave for broader tech sector By Mia Shanley With massive revenue growth and market share gains in the bag, online drug seller…

Read MORE »

Everest Medicines Ties With Tencent to Scale Last Mile to Patient Care

Back-to-back deals with Tencent and Medbanks Health seek to build new distributing partnerships ahead of expected first drug approvals Key points: Everest Medicines could gain valuable distribution channels through its new partnerships with Tencent and Medbanks Both new partners have users bases on ‘closed-loop’ healthcare platforms providing everything from checkups to drug sales By Richard Barbarossa What do cutting-edge cancer drugs and social media have in common? Not much, really. But that unlikely pairing is bringing together cancer and autoimmune disorder drug startup Everest Medicines Ltd. (1952.HK) and leading social…

Read MORE »

Online Drug Supplier 111 Finds Tonic in B2B Focus

Company adds two fulfillment centers, inks deal with cancer drug maker BeiGene, in drive to consolidate its place as premier B2B specialist Key takeaways 111 Inc.’s aggressive pursuit of partnerships with global drug makers and expansion of its regional logistics centers bodes well for its B2B business growth The company may have to further expand its consumer-focused online healthcare services if it wants to truly compete with omnichannels like Alibaba Health and JD Health. By Richard Barbarossa Online drug and healthcare services provider 111 Inc. (Nasdaq: YI) is rapidly building…

Read MORE »